Summary. Inclusion of the BCR±ABL ES probe in routine cytogenetics led to the identification of a subgroup of Philadelphia positive (Ph1) chronic myeloid leukaemia patients characterized by a 5 H -ABL deletion. This anomaly was observed in 5/51 cases (9´8%). Cytological and clinical data suggest that the 5 H -ABL deletion may be associated with dysplastic features of polymorphonuclear cells and metamyelocytes and a short chronic phase duration.
Bone marrow cells of 90±95% of chronic myeloid leukaemia (CML) patients harbour the Philadelphia chromosome, which results from the translocation t(9;22)(q34;q11) (Rowley, 1973) . At the molecular level, the translocation juxtaposes 3
H DNA sequences of the ABL oncogene mapping on 9q34.1 with 5 H DNA sequences of the BCR gene located on 22q11, giving rise to a chimaeric BCR±ABL fusion gene on the derivative 22 (Melo, 1996) .
New fluorescence in situ hybridization (FISH) strategies are now available that are highly sensitive to detect the BCR±ABL fusion gene on interphase nuclei (Bentz et al, 1994; Sinclair et al, 1997; Buno et al, 1998) . In this context, the LSI BCR±ABL ES (extra signal) dual-colour translocation probe was introduced by Vysis (Downer's Grove, IL, USA) in 1998. In this novel system, the ABL probe (650 kb) spans both sides of the breakpoint on 9q so that Ph1 cells show (i) co-localization of the BCR and ABL probes and (ii) the presence of a third independent fluorescent signal for ABL (split signal remaining on the derivative 9). Using this new system, we observed a deletion of the 5 H -ABL region in 5/51 Ph1 patients. We report here the clinical and cytogenetic findings for these five patients.
MATERIALS AND METHODS
Fifty-one consecutive patients were included in the study: 31 men and 20 women, aged 26±84 years (median 54´5 years). All patients were studied at diagnosis, before any therapy. The diagnosis of CML was based on typical peripheral blood findings and the presence of the Philadelphia chromosome in marrow cells. The patients were re-evaluated with the new LSI BCR±ABL ES probe. Five hundred nuclei/patients were analysed.
RESULTS
Although the expected signals for the BCR±ABL ES probe were observed in Ph1 cells from 46/51 cases, the remaining five patients (9´8%) showed an atypical hybridization pattern that resulted from the loss of the split ABL signal normally present on the derivative 9, which is consistent with a deletion of the 5 H -ABL region ( Fig 1A and B) . The clinical and cytogenetic data for these five patients are summarized in Table I . Interestingly, they presented with similar cytological features, including (i) small and monolobulated megakaryocytes (4/5 patients); (ii) polymorphonuclear cells and metamyelocytes with clumped chromatin (4/5 patients); (iii) Pelger-Hue Èt or Pelger-Hue Èt-like anomalies (3/5 patients) (P , 0´025); and (iv) dysgranulopoiesis including hypogranular and agranular elements (3/5 patients) (Table I) . Two patients presented with the four cytological features (P , 0´001).
Patients 1, 4 and 5 underwent bone marrow transplantation (BMT) in chronic phase (Table I) . Patient 2 developed an acceleration phase (AP) and a blast crisis (BC) 16 and 25 months, respectively, after diagnosis. An extra Ph chromosome was observed during acceleration and blast crisis in, respectively, 4% and 6% of the metaphases. He underwent BMT 29 months after diagnosis but died from neural infection. Patient 3 presented with acute myeloid leukaemia and 65% circulating blasts 9 months after diagnosis. No cytogenetic analysis was performed at that time. She died 3 months later.
DISCUSSION
Screening of CML patients with the BCR±ABL ES probe (Vysis) led to the identification of a subgroup of patients with a 5 H -ABL deletion, including the arginosuccinate synthetase gene. In our series, 5/51 patients (9´8%) showed both the BCR±ABL rearrangement and the 5 H -ABL deletion. Similar observations have been reported by Dewald et al (1998 Dewald et al ( , 1999 with the D-FISH probe from Oncor. They observed atypical hybridization patterns consistent with loss of 3 H -BCR, loss of 5 H -ABL or loss of both segments in 28/141 (19%) Ph1 CML patients (Dewald et al, 1999) . More particularly, the 5 H -ABL segment was lost in 17/141 (12%) patients.
However, it remains to be determined whether the 5 H -ABL deletion is to be considered as a secondary chromosomal change, heralding the evolution towards an acceleration phase (AP) or blast crisis (BC), or whether the deletion characterizes a subset of CML patients at diagnosis. In the light of our results, we cannot favour either of these two hypotheses. On the one hand, the FISH data indicated that the translocation and the deletion appeared in a one-step event as we were unable to detect a subclone with the expected hybridization pattern. On the other hand, patients with both the translocation and the submicroscopic deletion seemed to have particular cytological features associated with a short chronic phase duration. In our series, the mean duration of chronic phase for the two patients that developed an AP and/or BC was 12´5 months (9± 16 months). This interval is markedly shorter than the mean duration of chronic phase (30±60 months) reported in the literature (Sawyers, 1999) . The possible prognostic significance of the 5 H -ABL deletion was also noted in the study of Dewald et al (1998) , in which atypical hybridization patterns were observed in patients with masked Ph (five patients) or with additional chromosomal changes characteristic of the AP or BC phases (two patients). However, the observation of an extra Ph during AP and BC in one of our patient indicates that the 5 H -ABL deletion is probably not directly involved in acceleration or blast crisis. Nevertheless, the deletion could favour the emergence of additional chromosomal anomalies, the mechanism of which remains to be elucidated. H -ABL deletion, particular cytological features and a possible short chronic phase duration. However, our series is small and collection of large cohorts of patients is needed to assess these clinical findings. 
